[Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
Ajioka
Hirofusa
H
hiro-ajioka@taiho.co.jp
Morita
Fumio
F
Akizawa
Yushiro
Y
Yoshida
Kenichiro
K
Kitamura
Ryuichi
R
Takimoto
Hisami
H
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004347:Drug Interactions; D006801:Humans; D007275:Injections, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000970:Antineoplastic Agents; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D002945:Cisplatin